Codes of Conduct


The Code for Pharmaceutical Marketing has been adopted at the will and upon common agreement of IFPA and VGA – associations of companies engaged in pharmaceutical marketing in Lithuania. It seeks to ensure that member pharmaceutical companies engage in an ethical promotion, restraining from deceitful practices and potential conflicts of interest with healthcare professionals, whilst complying with applicable laws and regulations. Thus the Code seeks to enable an environment where the general public may be sure that the choices regarding their medicinal products are made based on the merit of each product and the patients’ clinical needs. This Code does not aim at restraining the promotion of medicinal products in such a way as to hinder free competition or limit interaction with healthcare professionals.

Lithuanian Association of Innovative Pharmaceutical Industry (hereinafter referred to as IFPA) is the association of companies engaged in the development and/or marketing of medicines in Lithuania. IFPA is member of the institution representing the pharmaceutical industry in Europe, the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The Pharmaceutical Manufacturers’ Association (hereinafter referred to as VGA) is the association of companies which develop, produce and/or are engaged in the marketing of medicines and their representatives in Lithuania.

Both associations (IFPA and VGA) contribute to EFPIA mission – to promote pharmaceutical research and development and the best conditions in Europe for companies to bring to patients new medicines that improve human health and the quality of life around the world.

Members of IFPA and VGA are aware of the importance of providing accurate, fair and objective information about medicinal products enabling people to make informed decisions about the use of specific medicinal products. Building upon this goal, IFPA and VGA approved the Code of Ethics for Pharmaceutical Marketing, which governs pharmaceutical marketing and relations with pharmaceutical professionals and healthcare professionals as well as relations between the pharmaceutical industry and patient organisations (hereinafter referred to as Code). The Code has been developed according to the Code of Ethics adopted in Lithuania in 2004 in compliance with the provisions of the EFPIA code and general ethical principles as amended on 24 June 2010 and on 14 June 2011. It also reflects the requirements of the EU Council Directive 2001/83/EC, as amended, (hereinafter referred to as Directive) concerning the use of medicinal products for human use. The Code is consistent with the general provisions of the Directive, which acknowledge voluntary control over promotion of medicinal products implemented through organisations/institutions which represent the pharmaceutical industry sector by providing the opportunity to apply to such organisations when complaints occur. In addition, the Code incorporates the principles set out in the Law on Pharmaceutics of the Republic of Lithuania (Official Gazette, 2006 No. 78-3056), the Law on Advertising of the Republic of Lithuania (Official Gazette, 2000, No. 64-1937, 2002, No. 123-5508) and the Law on Provision of Information to the Public of the Republic of Lithuania (Official Gazette 1996, No. 71-1706, 2000, No. 75-2272, 2006, No. 82-3254).